Introduction
Toxic epidermal necrolysis, often abbreviated as TEN, is a rare but life-threatening severe skin reaction. It is usually identified through a combination of clinical findings, medication history, and targeted testing rather than by a single definitive bedside sign. The disorder belongs to the spectrum of severe cutaneous adverse reactions and is characterized by extensive death of keratinocytes, the cells that form the outer layer of the skin and line mucosal surfaces. This cell injury leads to skin detachment, blistering, and erosions that can resemble burns.
Accurate diagnosis is important because TEN progresses quickly and can cause major fluid loss, infection, airway involvement, eye damage, and death. It also requires immediate removal of the triggering drug if one is present, along with intensive supportive care. Since other skin disorders can look similar early on, clinicians must distinguish TEN from conditions such as Stevens-Johnson syndrome, staphylococcal scalded skin syndrome, autoimmune blistering diseases, and severe drug eruptions. Diagnostic reasoning therefore focuses on the pattern of skin injury, the timing of symptoms relative to medication exposure, and confirmation by tissue examination when needed.
Recognizing Possible Signs of the Condition
The first suspicion of TEN usually comes from the combination of a recent drug exposure and rapidly worsening skin and mucosal symptoms. In many cases, the illness begins with nonspecific complaints such as fever, malaise, sore throat, cough, burning eyes, or body aches before the skin findings become obvious. These early symptoms may resemble a viral illness, which is one reason diagnosis can be delayed.
The skin findings that raise concern are typically painful rather than itchy. Patients may develop widespread erythematous or dusky macules, atypical target-like lesions, or areas of tenderness that evolve into blisters and sheet-like skin detachment. A key feature is that the skin often separates with gentle pressure, reflecting loss of adhesion between epidermal layers. This phenomenon is commonly described as positive Nikolsky sign, although it is not unique to TEN and is not sufficient by itself to make the diagnosis.
Mucosal involvement is especially important. TEN frequently affects the mouth, lips, eyes, and genital mucosa. Painful oral erosions, conjunctival redness, photophobia, difficulty swallowing, and painful urination or genital erosions strongly support the diagnosis. In contrast to many ordinary drug rashes, TEN usually causes significant skin tenderness and extensive mucosal damage. The extent of detached or detachable skin is also a clue: when more than 30 percent of the body surface area is involved, the process is classified as TEN rather than Stevens-Johnson syndrome, which involves less than 10 percent. Intermediate cases are often referred to as overlap syndrome.
Medical History and Physical Examination
Diagnosis begins with a careful history. Clinicians focus on medication use in the weeks before symptom onset, because TEN most often results from a delayed immune-mediated reaction to a drug. The highest-risk period is usually within the first one to three weeks after starting a new medication, although reactions can occur later. Doctors ask about prescription drugs, over-the-counter medicines, herbal products, and recent dose changes. Commonly implicated drugs include certain anticonvulsants, sulfonamide antibiotics, allopurinol, some NSAIDs, and specific antiretroviral or targeted therapies.
A history of prior severe drug reaction, recent infection, immunosuppression, or underlying chronic illness may also be relevant. Because TEN is a cell-mediated hypersensitivity reaction, the clinician is often looking for a temporal relationship between drug exposure and a rapidly evolving immune injury pattern rather than an infectious source. The history may also reveal prodromal symptoms, prior mucosal discomfort, or a progression from fever and eye irritation to widespread painful rash.
Physical examination is directed at assessing the extent and severity of skin and mucosal involvement. Doctors inspect the entire skin surface for erythema, dusky discoloration, blistering, erosion, and detachment. They estimate the body surface area involved, since this affects classification and prognosis. Mucosal surfaces are carefully examined, including the mouth, eyes, nose, genital area, and sometimes the respiratory tract if symptoms suggest involvement. Vital signs and overall hydration are checked because fever, tachycardia, hypotension, and signs of fluid loss may indicate systemic compromise.
Eye examination is especially important because ocular damage can lead to lasting complications such as scarring, dry eye, and visual impairment. Many patients require urgent ophthalmology evaluation. Clinicians also assess for secondary infection, respiratory distress, and pain out of proportion to visible lesions. The severity of tenderness and the rapid progression of lesions help distinguish TEN from less dangerous eruptions.
Diagnostic Tests Used for Toxic epidermal necrolysis
There is no single blood test that confirms TEN on its own. Diagnosis relies on a combination of laboratory evaluation, tissue examination, and exclusion of alternative conditions. Tests are used to assess the severity of illness, look for complications, and support the clinical impression.
Laboratory tests are commonly obtained early. A complete blood count may show leukopenia, anemia, or evidence of infection. Electrolytes, blood urea nitrogen, creatinine, and liver enzymes help determine whether dehydration, kidney injury, or hepatic involvement is present. These values are important because TEN can cause major fluid shifts and multiorgan stress. Serum albumin may be low in severely ill patients. Blood cultures or wound cultures may be ordered if infection or sepsis is a concern, although positive cultures do not establish the diagnosis of TEN itself.
Clinicians may also use laboratory data to calculate prognostic scores, such as SCORTEN, which estimates mortality risk using factors like age, heart rate, malignancy, detached skin area, serum urea, glucose, and bicarbonate level. SCORTEN does not diagnose TEN, but it helps guide intensity of care.
Tissue examination is the most useful confirmatory test when the diagnosis is uncertain. A skin biopsy from an early lesion or edge of an active blister typically shows full-thickness epidermal necrosis, sparse or absent inflammatory infiltrate, and separation of the epidermis from the dermis. This histology reflects the underlying pathophysiology: widespread apoptotic death of keratinocytes driven by immune-mediated cytotoxic injury, rather than simple superficial inflammation. Direct immunofluorescence may be performed to exclude autoimmune blistering disorders; in TEN, it is usually negative or nonspecific.
Imaging tests are not used to diagnose TEN directly, but they can be helpful when complications are suspected. Chest imaging may be considered if respiratory symptoms suggest pneumonia, aspiration, or mucosal sloughing in the airway. Abdominal or other imaging is only used selectively if another process is being considered. In most cases, imaging plays a secondary role compared with examination and biopsy.
Functional tests are also supportive rather than diagnostic. Eye evaluations assess tear production, conjunctival inflammation, and corneal involvement. Pulmonary or airway assessment may be needed if there is hoarseness, cough, dyspnea, or suspected mucosal injury. These tests help determine organ involvement and complications, not the diagnosis itself.
Interpreting Diagnostic Results
Doctors interpret the findings as a pattern rather than relying on any single abnormal result. When a patient has a recent exposure to a high-risk medication, rapidly progressive painful skin lesions, mucosal erosion, and extensive epidermal detachment, TEN becomes highly likely. A biopsy showing widespread keratinocyte necrosis strongly supports the diagnosis, especially when the clinical picture is consistent.
The biopsy is particularly useful when the rash could be caused by another disorder. In TEN, the degree of epidermal death is usually extensive and the inflammatory infiltrate is relatively sparse. This differs from inflammatory dermatoses or autoimmune blistering diseases, which often show different patterns of immune deposition or cellular infiltration. Negative direct immunofluorescence also helps exclude pemphigus vulgaris, bullous pemphigoid, and related conditions.
Laboratory abnormalities are interpreted as markers of severity and complications. Elevated creatinine may reflect dehydration, sepsis, or acute kidney injury. Abnormal liver function tests may indicate organ stress or drug toxicity. Blood gas abnormalities or low bicarbonate can suggest severe systemic illness and are associated with worse prognosis. These findings do not prove TEN, but they strengthen the need for urgent treatment and monitoring.
Clinical classification depends on the amount of skin detachment. If detachment involves less than 10 percent of body surface area, the process is classified as Stevens-Johnson syndrome. Between 10 and 30 percent is overlap syndrome, and more than 30 percent is TEN. Because these entities exist on a continuum, doctors use the same diagnostic framework but assign the label according to extent.
Conditions That May Need to Be Distinguished
Several disorders can resemble TEN, especially in the first days before full skin detachment appears. Stevens-Johnson syndrome is the closest related condition and is distinguished mainly by the smaller extent of epidermal loss. Both share similar triggers and pathobiology, so the distinction is one of severity rather than a completely separate disease process.
Staphylococcal scalded skin syndrome can also cause widespread skin peeling and a positive Nikolsky sign, but it is caused by bacterial toxins, occurs more often in infants and young children, and usually has minimal mucosal involvement. Skin biopsy can distinguish it because the level of cleavage is more superficial and there is not full-thickness epidermal necrosis.
Other possibilities include generalized bullous fixed drug eruption, acute generalized exanthematous pustulosis, pemphigus vulgaris, bullous pemphigoid, paraneoplastic pemphigus, and erythema multiforme major. Autoimmune blistering diseases are differentiated by biopsy and immunofluorescence patterns. Erythema multiforme major often has more distinct target lesions and a different clinical course. Toxic shock syndrome, graft-versus-host disease, and extensive burns may also enter the differential depending on the context. Clinicians use the pattern of mucosal involvement, medication timing, histology, and systemic findings to separate these entities.
Factors That Influence Diagnosis
Several factors affect how quickly and confidently TEN is diagnosed. Severity of illness is one of the most important. In patients with extensive skin sloughing, the diagnosis may be clinically obvious, whereas early or limited cases can be difficult to recognize. A high index of suspicion is required when a patient develops painful rash and mucosal symptoms soon after starting a new medication.
Age can influence presentation and interpretation. Children may be less likely to have certain classic drug triggers, and they may present differently from adults. Older adults often have more comorbidities, take multiple medications, and may be at greater risk of delayed recognition because symptoms can be misattributed to infection or another drug reaction.
Underlying medical conditions also matter. Immunosuppression, HIV infection, malignancy, kidney disease, or recent transplantation can broaden the differential diagnosis and alter laboratory values. These conditions may increase susceptibility to severe drug reactions and complicate interpretation of fever, cytopenias, or organ dysfunction.
Timing of biopsy and treatment can also affect diagnostic yield. If the biopsy is taken too late, tissue may be more denuded and less informative. If corticosteroids, immunomodulators, or extensive wound care are started before evaluation, some features may become less obvious, though diagnosis is still often possible. Access to dermatology, ophthalmology, and pathology services influences speed and certainty of confirmation.
Conclusion
Toxic epidermal necrolysis is diagnosed through careful clinical assessment supported by targeted tests. Physicians look for a characteristic sequence of recent drug exposure, prodromal illness, painful skin eruption, mucosal involvement, and extensive epidermal detachment. Laboratory studies assess severity and complications, while skin biopsy provides the most useful confirmation when the diagnosis is uncertain. Other blistering and peeling disorders must be excluded, often with the help of histology and immunofluorescence. Because TEN can progress rapidly and cause major organ-related complications, prompt and accurate diagnosis is essential for stopping the causative drug, guiding supportive care, and improving outcomes.